-transparent.png){kind=logo}
BACKGROUND The purpose of this randomized double-blind, placebo-controlled study was to compare the efficacy and safety of fluoxetine plus group psychotherapy versus group psychotherapy alone in HIV-seropositive men (based on 1986 CDC classes II, III, and IV.C.2) who had been diagnosed with major depressive disorder (DSM-III-R). METHODS During a 7-week trial, patients were treated with fluoxetine 20-60 mg or placebo 1-3 capsules per day and were seen in weekly supportive group psychotherapy. In addition, subjects were rated on the 17-item Hamilton Rating Scale for Depression (HAM-D-17), Clinical Global Impressions scales for Improvement (CGI-I) and Severity of Illness (CGI-S), and the short version of the Beck Depression Inventory (BDI-13). Of the 47 patients enrolled in the study, 25 were administered fluoxetine and 22 were given placebo. RESULTS Subjects who received fluoxetine began to show significantly more improvement than patients who received placebo on both self- and observer-rated scales by the end of the first week of treatment. By endpoint, patients treated with fluoxetine experienced greater mean changes from baseline compared with placebo-treated patients on the HAM-D-17 (12.1 vs. 6.6; F = 6.53, df = 1,45; p < .05) and BDI-13 (5.9 vs. 1.2; F = 5.73, df = 1,45; p < .05), and a greater percentage of fluoxetine-treated patients experienced a > or = 50% in HAM-D-17 scores (64% vs. 23%; chi2= 8.60, df = 1, p < .01). Differences were particularly apparent in subjects whose initial depressive episodes were rated as severe (i.e., HAM-D-17 score > or = 24). Severely depressed patients treated with fluoxetine had an endpoint CGI-I of 1.4 compared with an endpoint CGI-I of 2.7 for patients treated with placebo (F = 6.02, df = 1,11; p < .05). Further, side effects were generally mild and transient. The most frequently noted effects reported by subjects treated with fluoxetine were nausea, dry mouth, headache, and diarrhea, in decreasing order of frequency. CONCLUSIONS This study supports the efficacy and safety of fluoxetine over and above group psychotherapy for the treatment of HIV-associated major depression.
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
September 1997,
Journal of the International Neuropsychological Society : JINS,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
November 1995,
Psychiatry,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
August 1992,
The American journal of psychiatry,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
July 1991,
American journal of psychotherapy,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
December 1992,
Archives of neurology,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
January 1996,
Women & health,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
January 1995,
Current topics in microbiology and immunology,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
January 2000,
Journal of the International Neuropsychological Society : JINS,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
January 1993,
Women & health,
S Zisook, and
J Peterkin, and
K J Goggin, and
P Sledge, and
J H Atkinson, and
I Grant
February 1999,
Investigative ophthalmology & visual science,
